依达拉奉联合尼莫地平治疗急性大面积脑梗死的疗效分析

发布时间：2018-03-01 10:06

本文关键词： 依达拉奉尼莫地平急性脑梗死大面积疗效安全性神经功能　出处：《中国药房》2017年09期 　论文类型：期刊论文

【摘要】：目的:探讨依达拉奉联合尼莫地平治疗急性大面积脑梗死患者的疗效和安全性。方法:回顾性分析101例急性大面积脑梗死患者资料,按用药的不同分为对照组(53例)和观察组(48例)。入院后,对照组患者均采用减轻脑水肿、抗凝、抗血小板凝聚等常规治疗;观察组患者在对照组治疗的基础上给予依达拉奉注射液30 mg,加入0.9%氯化钠注射液100 m L中,静脉滴注,30min内滴完,每日2次+尼莫地平注射液12 mg,加入0.9%氯化钠注射液500 m L中,静脉滴注,每日1次,滴速为0.5μg/(kg·min),连用10 d,后改用口服尼莫地平片60 mg,每日3次,连用5 d。两组疗程均为15 d。观察两组患者的临床疗效,治疗前后血氧饱和度(Sp O2)、血红蛋白(Hb)、血红蛋白总量(HBT)、还原血红蛋白(MHb)、神经功能缺损程度(NIHSS)评分及不良反应发生情况。结果:观察组患者总有效率显著高于对照组,差异有统计学意义(P0.05)。治疗前,两组患者SpO_2、Hb、HBT、MHb水平及NIHSS评分比较,差异均无统计学意义(P0.05)。治疗后,两组患者Sp O2、HBT、MHb水平均显著高于同组治疗前,且观察组显著高于对照组;两组患者NIHSS评分均显著低于同组治疗前,且观察组显著低于对照组;两组患者Hb水平显著低于同组治疗前,差异均有统计学意义(P0.05),但两组间Hb水平比较差异均无统计学意义(P0.05)。两组患者治疗期间均未见明显不良反应发生。结论:在常规治疗的基础上,依达拉奉联合尼莫地平治疗急性大面积脑梗死的疗效显著,能改善患者神经功能缺损程度,且未增加不良反应的发生。
[Abstract]:Objective: to investigate the efficacy and safety of Edaravone combined with nimodipine in the treatment of acute large area cerebral infarction. After admission, the patients in the control group were treated with routine therapy such as reducing brain edema, anticoagulation, anti-platelet aggregation and so on, and the patients in the control group were divided into two groups: control group (n = 53) and observation group (n = 48). The patients in the observation group were given Edaravone injection 30 mg on the basis of treatment in the control group. The patients in the observation group were injected with 0.9% mL sodium chloride injection within 30 minutes after intravenous drip, 12 mg of nimodipine injection twice a day, and 0.9% mL of sodium chloride injection. Intravenous drip, once a day, at a rate of 0.5 渭 g / kg 路min, for 10 days, followed by oral nimodipine 60 mg, 3 times a day for 5 days. The course of treatment in both groups was 15 days. The clinical efficacy of the two groups was observed. Before and after treatment, the scores of blood oxygen saturation (SpO _ 2), hemoglobin (HB), total hemoglobin (HBT), reduced hemoglobin (HBT), degree of neurological impairment (NIH), and adverse reactions occurred. Results: the total effective rate of the patients in the observation group was significantly higher than that in the control group, and the total effective rate was significantly higher in the observation group than in the control group. Before treatment, there was no significant difference between the two groups in the level of SpO2Hb HBTmHb and the score of NIHSS. After treatment, the levels of SpO2-HBTmHb in the two groups were significantly higher than those in the same group, and the observation group was significantly higher than the control group. The NIHSS score of the two groups was significantly lower than that of the same group before treatment, and that of the observation group was significantly lower than that of the control group, and the HB level of the two groups was significantly lower than that of the same group before treatment. The difference was statistically significant (P 0.05), but there was no significant difference in HB level between the two groups. There were no significant adverse reactions in both groups during treatment. Conclusion: on the basis of routine therapy, no significant adverse reactions occurred in the two groups. Edaravone combined with nimodipine was effective in the treatment of acute large area cerebral infarction. It could improve the degree of neurological deficit and did not increase the incidence of adverse reactions.
【作者单位】：江苏大学附属医院/宜兴市人民医院急诊科;江苏大学基础医学院;
【分类号】：R743.33

【参考文献】